On 24 April 2019, orphan designation (EU/3/19/2157) was granted by the European Commission to Dipharma B.V., the Netherlands, for sodium benzoate, sodium phenylacetate for the treatment of ornithine transcarbamylase deficiency.
|Disease / condition||
Treatment of ornithine transcarbamylase deficiency
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.